Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Therapeutic Potential of LPCN 1154 for the Treatment of Postpartum Depression (PPD) in Adults

Next Previous
Trial Profile

A Phase 2 Study to Evaluate the Therapeutic Potential of LPCN 1154 for the Treatment of Postpartum Depression (PPD) in Adults

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexanolone (Primary)
  • Indications Postnatal depression
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Lipocine

Most Recent Events

  • 10 Mar 2023 According to a Lipocine media release, the proof-of-concept study is a prelude to a pivotal study required for NDA filing.
  • 08 Aug 2022 According to a Lipocine media release, the company plans to initiate a multi-dose proof-of-concept study of LPCN 1154 in the second half of 2022.
  • 05 Aug 2021 According to a Lipocine media release, the company expects to initiate this study in the fourth quarter of 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top